ozanimod vs Tascenso ODT
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT01628393 · Phase 2/3 · completed
The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.
Next expected readout: August 2028 · NCT06529406 (registry estimate)
Reported efficacy
Adjusted Annualized Relapse Rate (ARR) at the End of Month 24: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose (met)
Result source: NCT02047734
Tascenso ODT
Marketed by Cycle Pharmaceuticals Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ozanimod | Tascenso ODT |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3vs Interferon Beta-1aNCT020477345 other results
| —Not reported |
| Free of 3-month confirmed disability progression (%) | —Trial running · NCT06408259 | —Not reported |
| New or enlarging T2 lesions | 0.8 vs 9−8.2 vs placeboNCT016283931 other result
| —Not reported |
Annualised relapse rate
- ozanimod
- 0.2 vs 0.3vs Interferon Beta-1aNCT02047734
5 other results
- 0.2 vs 0.3 NCT02294058
- 0.2 vs 0.3 NCT02047734
- 0.2 vs 0.3 NCT02294058
- 0.2 vs 0.5 NCT01628393
- 0.3 vs 0.5 NCT01628393
- Tascenso ODT
- —Not reported
Free of 3-month confirmed disability progression (%)
- ozanimod
- —Trial running · NCT06408259
- Tascenso ODT
- —Not reported
New or enlarging T2 lesions
- ozanimod
- 0.8 vs 9−8.2 vs placeboNCT01628393
1 other result
- 1.4 vs 9 NCT01628393
- Tascenso ODT
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Tascenso ODT: no structured comparison results are available for Multiple Sclerosis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ozanimod: 4 of 4 rows · Tascenso ODT: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ozanimod |
|---|---|
| Dropout rate | —1.0 mga NCT01628393 · Phase 2/3 show 11 more results1.2%1 mg NCT01628393 · Phase 2/3 —1.0 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 2.3%0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 10.6%1 mg NCT02047734 · Phase 3 15.6%0.5 mg NCT02047734 · Phase 3 6.5%1 mg NCT02294058 · Phase 3 5.8%0.5 mg NCT02294058 · Phase 3 20.9%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 21%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —1.0 mga NCT01628393 · Phase 2/3 show 11 more results—1 mg NCT01628393 · Phase 2/3 —1.0 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 3%1 mg NCT02047734 · Phase 3 2.9%0.5 mg NCT02047734 · Phase 3 2.9%1 mg NCT02294058 · Phase 3 1.6%0.5 mg NCT02294058 · Phase 3 3%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 3.7%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 7.3%1.0 mga NCT01628393 · Phase 2/3 show 11 more results—1 mg NCT01628393 · Phase 2/3 0%1.0 mg NCT01628393 · Phase 2/3 7.9%0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 3.4%0.5 mg NCT01628393 · Phase 2/3 6.5%1 mg NCT02047734 · Phase 3 7.1%0.5 mg NCT02047734 · Phase 3 2.9%1 mg NCT02294058 · Phase 3 3.5%0.5 mg NCT02294058 · Phase 3 15.5%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 15.7%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 1.0 mga nasopharyngitis 13.8% (placebo 13.6%) alanine aminotransferase increased 9.8% (placebo 0%) upper respiratory tract infection 8.9% (placebo 3.4%) NCT01628393 · Phase 2/3 show 9 more results1.0 mg gamma-glutamyltransferase increased 6% (placebo 0%) nasopharyngitis 6% (placebo 13.6%) alanine aminotransferase increased 4.8% (placebo 0%) NCT01628393 · Phase 2/3 0.5 mg upper respiratory tract infection 15.9% (placebo 3.4%) nasopharyngitis 13.5% (placebo 13.6%) gamma-glutamyltransferase increased 8.7% (placebo 0%) NCT01628393 · Phase 2/3 0.5 mg nasopharyngitis 12.6% (placebo 13.6%) urinary tract infection 6.9% (placebo 2.3%) back pain 5.7% (placebo 10.2%) NCT01628393 · Phase 2/3 0.5 mg nasopharyngitis 13.4% headache 12.5% upper respiratory tract infection 8.2% NCT02047734 · Phase 3 1.0 mg nasopharyngitis 20.9% (placebo 13.5%) headache 17% (placebo 5.4%) covid-19 16.1% (placebo 21.6%) NCT02576717 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 21% (placebo 13.5%) headache 16.9% (placebo 5.4%) covid-19 15.5% (placebo 21.6%) NCT02576717 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ozanimod
show 7 more results
show 1 more result
show 5 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · Tascenso ODT's landscape